Revised maximum retail prices (MRPs) of 1,364 anti-cancer formulations came into effect on November 9, marking a significant step towards reducing the financial burden of cancer treatment in India. Following a government decision to cap trade margins on 137 non-scheduled anti-cancer medicines, consumers are expected to save approximately ₹3,540.38 crore annually.

Why the Government Introduced the Price Intervention

Cancer treatment remains prohibitively expensive for many Indian families, particularly when patients require prolonged therapies or advanced medicines. While several essential medicines are subject to formal price controls, many non-scheduled anti-cancer drugs have historically carried substantial distribution and retail margins, contributing to high consumer prices.

To address this gap, the National Pharmaceutical Pricing Authority (NPPA) introduced Trade Margin Rationalisation (TMR). Instead of directly fixing manufacturers’ prices, the measure limits the trade margin between the distributor and the final retail price.

On October 17, 2026, the NPPA capped trade margins on 137 non-scheduled anti-cancer medicines, including patented drugs, at 30% of the MRP. The revised prices were calculated using the average price at which distributors purchased the medicines in March 2026, with applicable GST added separately.

1,364 Formulations See Revised Prices

The scale of the revision is substantial. By November 8, a total of 85 pharmaceutical companies had reported revised MRPs covering 1,364 formulations across 121 drugs.

Key developments include:

·       679 brands recorded price reductions exceeding 50%.

·       The steepest reported reduction was 96.45%.

·       The price revisions cover multiple anti-cancer formulations, including medicines used in advanced cancer treatment.

·       Estimated annual savings for consumers stand at ₹3,540.38 crore.

The NPPA will continue updating the revised-price list as additional companies submit their pricing information.

What the Decision Means for Cancer Patients

The intervention could significantly reduce out-of-pocket expenditure for patients, particularly those dependent on expensive medicines over extended periods. Lower prices may also improve treatment continuity, reduce financial distress and make certain therapies more accessible to families without comprehensive health insurance.

However, the actual benefit will depend on the availability of medicines, compliance by pharmaceutical companies and retailers, and whether patients receive the revised prices at the point of purchase. Patients who are charged above the revised MRP or encounter medicine-pricing irregularities can approach the NPPA through the Pharma Jan Samadhan portal or contact its helpline at 1800-111-255.

Making Affordable Cancer Care a Reality

The revised MRPs represent an important regulatory intervention, but affordability cannot be measured by price reductions alone. Effective implementation, transparent billing, uninterrupted medicine supplies and strict monitoring of retailers will determine its real impact. The estimated ₹3,540-crore annual saving offers considerable hope; ensuring that this relief reaches every eligible patient must now become the priority.

(With agency inputs)